亿帆医药(002019) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 1,326,616,043.20, a slight increase of 0.05% compared to CNY 1,325,969,392.93 in the same period last year[5] - Net profit attributable to shareholders was CNY 153,161,633.89, representing a growth of 4.83% from CNY 146,099,164.96 year-on-year[5] - The net profit after deducting non-recurring gains and losses decreased by 13.55% to CNY 95,369,685.69 from CNY 110,319,647.03 in the previous year[5] - Total revenue for the current period reached ¥1,326,616,043.20, slightly up from ¥1,325,969,392.93 in the previous period, indicating a growth of approximately 0.05%[22] - The net profit for the current period is CNY 138,229,631.62, an increase from CNY 117,548,462.21 in the previous period, representing a growth of approximately 17.4%[23] - The total comprehensive income for the current period is CNY 158,904,733.40, compared to CNY 103,628,790.72 in the previous period, indicating a significant increase of about 53.4%[23] - The basic and diluted earnings per share for the current period are both CNY 0.1259, up from CNY 0.1201 in the previous period, representing an increase of approximately 4.8%[23] Cash Flow and Assets - Operating cash flow for the period was CNY 182,335,417.29, up by 0.83% from CNY 180,839,724.48 in the same quarter last year[5] - Cash and cash equivalents decreased to ¥874,295,606.70 from ¥889,388,507.75, a decline of approximately 1.03%[18] - Cash and cash equivalents at the end of the period decreased to CNY 768,385,206.69 from CNY 688,839,805.94, reflecting a decline of approximately 14.5%[26] - The net cash outflow from investing activities for the current period is CNY -107,357,698.14, compared to CNY -76,271,060.87 in the previous period, reflecting a larger outflow[25] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 12,510,887,760.92, an increase of 1.83% from CNY 12,285,788,088.75 at the end of the previous year[5] - Total liabilities increased to ¥3,923,026,883.24 from ¥3,858,992,750.77, marking a rise of approximately 1.67%[19] - The company's equity attributable to shareholders increased by 2.06% to CNY 8,697,424,767.68 from CNY 8,521,867,867.56 at the end of the last year[5] - The company's equity attributable to shareholders rose to ¥8,697,424,767.68 from ¥8,521,867,867.56, an increase of about 2.06%[20] Operating Costs and Expenses - Total operating costs increased to ¥1,200,723,203.71 from ¥1,189,455,724.43, reflecting a rise of about 0.22%[22] - Research and development expenses for the current period were ¥63,503,366.31, compared to ¥59,876,908.40 in the previous period, indicating an increase of approximately 6.93%[22] - The company reported a tax expense of CNY 18,453,067.29, down from CNY 41,365,369.65 in the previous period, showing a decrease of about 55.5%[23] - Financial expenses decreased by 48.66% to CNY 8,896,429.66, attributed to increased exchange gains and reduced interest expenses[9] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,858, with the largest shareholder holding 40.82% of the shares[11] - The top ten unrestricted shareholders hold a total of 124,131,577 shares, with Cheng Xianfeng being the largest shareholder[12] - The company has not reported any changes in the participation of top shareholders in margin trading activities[13] - The company has not identified any related party relationships among shareholders beyond those disclosed[12] - The total number of shares held by the top ten unrestricted shareholders includes significant stakes from various investment funds and individuals[12] Strategic Developments - The company received government subsidies amounting to CNY 58,918,080.80 during the reporting period, which significantly contributed to its financial performance[6] - The company continues to focus on expanding its product portfolio and enhancing its market presence through strategic initiatives[14] - The subsidiary Yifan Pharmaceutical Co., Ltd. received a drug registration certificate for Ambrisentan oral solution on March 10, 2025[14] - The subsidiary Yiyisheng Biopharmaceutical (Beijing) Co., Ltd. received approval for a supplemental application for Aibegesitin α injection on March 21, 2025, changing the administration timing[14] - Two subsidiaries achieved high-tech enterprise certification in February 2025, enhancing their innovation capabilities[15] Future Outlook - The company expects to turn a profit in 2024, as indicated in the earnings forecast released on January 24, 2025[13] - The controlling shareholder, Cheng Xianfeng, has pledged part of his shares as of February 20, 2025, indicating potential liquidity management[16]